| Oct 22 |
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
|
| Oct 9 |
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Oct 9 |
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
|
| Oct 8 |
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
|
| Oct 4 |
EU regulators reviewing safety of finasteride, dutasteride
|
| Sep 30 |
Organon reports positive phase 3 results on Roche Perjeta biosimilar
|
| Sep 30 |
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
|
| Sep 26 |
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada
|
| Sep 25 |
Are Options Traders Betting on a Big Move in Organon (OGN) Stock?
|
| Sep 22 |
Organon: A Surprising Deal
|
